Please login to the form below

Not currently logged in
Email:
Password:

Receptos

This page shows the latest Receptos news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

Ozanimod was acquired by Celgene as part of its $7.2bn takeover of Receptos in 2015, part of a drive to expand its business beyond cancer, a view reiterated by Celgene

Latest news

  • Celgene spends $7.2bn on Receptos purchase Celgene spends $7.2bn on Receptos purchase

    Celgene spends $7.2bn on Receptos purchase. Latest deal forms part of a major spending spree for the firm. ... Celgene will spend $7.2bn to acquire immune and inflammatory specialist Receptos as it looks to broaden its portfolio outside of oncology.

  • Receptos rejected AZ takeover bid, say sources Receptos rejected AZ takeover bid, say sources

    Receptos rejected AZ takeover bid, say sources. Sources also claim the Delaware-based firm is being chased by Gilead Sciences and Teva. ... Receptos' main asset is oxanimod (RPC1063), a sphingosine 1-phosphate 1 receptor (S1P1R) modulator in phase III

  • MS market set to grow 4% annually

    When it comes to branded medicines, Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063 are the projected

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene's acquisition of Receptos for $7.2bn is, according to Reuters, rumoured to have been too high a price for AstraZeneca (AZ), Gilead and Teva. ... Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of

  • Pharma deals during March 2013 Pharma deals during March 2013

    Receptos will conduct a phase II proof-of-concept study in Eosinophilic Esophagitis, an orphan indication in the US. ... Receptos will also be eligible for double digit royalties on net sales outside of the US.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics